ADP receptor inhibitors — Competitive Intelligence Brief

ADP receptor inhibitors (ADP receptor inhibitors) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ADP receptor inhibitor. Area: Cardiovascular.

phase 2 ADP receptor inhibitor P2Y12 Cardiovascular Small molecule

Target snapshot

ADP receptor inhibitors (ADP receptor inhibitors) — Eli Lilly and Company. ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ADP receptor inhibitors TARGET	ADP receptor inhibitors	Eli Lilly and Company	phase 2	ADP receptor inhibitor	P2Y12
Ticlid	TICLOPIDINE		marketed	ADP receptor antagonist	P2Y12	1991-01-01
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
aspirin and/or clopidogrel	aspirin and/or clopidogrel	Asan Medical Center	marketed	Antiplatelet agent	COX (aspirin); P2Y12 receptor (clopidogrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
Clopidogrel only	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ADP receptor inhibitor class)

1. Eli Lilly and Company · 1 drug in this class